Supplementary Table S1 from A Phase Ib/II Randomized Clinical Trial of Oleclumab with or without Durvalumab plus Chemotherapy in Patients with Metastatic Pancreatic Ductal Adenocarcinoma
Year: 2024
Type: supplementary-materials
Abstract: Patient demographics and disease characteristics (dose-escalation phase, as-treated population; N = 25)
Authors: Andrew L. Coveler, Matthew J. Reilley, Mark Zalupski, Teresa Macarulla, Christos Fountzilas, Mariano Ponz-Sarvisé, Adnan Nagrial, Nataliya V. Uboha, Sophia Frentzas, Michael Overman, Anne Noonan, Wells A. Messersmith, Nick Pavlakis, Niharika B. Mettu, Ina Bisha, Ying Wang, Paul Smith, Elina Murtomaki, Agata A. Bielska, Veronique Bragulat, Zachary A. Cooper, Rakesh Kumar, David R. Spigel
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
OpenAlex ID: W4403437077